Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | EYA3 | Q99504 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ME2 | P23368 | 1/20 | 0.39 |
| ▸ | ME1 | P48163 | 1/20 | 0.39 |
| ▸ | ME3 | Q16798 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15782860 | 0.86 | CA12 (0.44) | PRKCIHTTME2ME1ME3 | |
| SCHEMBL11434871 | 0.83 | BID (0.55) | ME2ME1ME3MAPT | |
| SCHEMBL6545119 | 0.82 | TLR8 (0.47) | TLR8ESR1ESR2GPR84MAPT | |
| SCHEMBL19841039 | 0.81 | PRKCI (0.38) | PRKCIHTTCA12 | |
| SCHEMBL24079188 | 0.81 | PRKCI (0.46) | PRKCIMAPT | |
| SCHEMBL10337577 | 0.79 | TLR8 (0.45) | TLR8GPR84LMNAMAPT | |
| SCHEMBL887833 | 0.79 | KDM4E (0.49) | TLR8LMNA | |
| SCHEMBL10933263 | 0.77 | TLR8 (0.49) | TLR8HTTMAPT | |
| SCHEMBL21569596 | 0.77 | NCEH1 (0.46) | PRKCIEYA3LMNAHTTMAPT | |
| SCHEMBL24079189 | 0.77 | PPARA (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12163968-B2 | Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers | BIO-RAD LABORATORIES, INC. (US) | 2024-12-10 | — | — | US | claimed |
| US-12163968-B2 | Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers | BIO-RAD LABORATORIES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4208021-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | Bio-Rad Laboratories, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116097093-A | Preparation of Nucleated RBC (NRBC) analogs for use as reference blood controls in automated blood analyzers | 生物辐射实验室股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022051443-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | BIO-RAD LABORATORIES, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220065878-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | BIO-RAD LABORATORIES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-10669244-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-02 | — | — | US | disclosed |
| EP-2376908-B1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | BIO RAD LABORATORIES (US) | 2014-12-31 | — | — | EP | disclosed |
| US-8114580-B2 | Simulation of normal fresh blood platelets for reference control | BIO-RAD LABORATORIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2376908-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | Bio-Rad Laboratories, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010083130-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | BIO-RAD LABORATORIES, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100178647-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | BIO-RAD LABORATORIES, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669244-B2 | Synthesis of tetracyclines and analogues thereof | TET1, TET3, MYC | PRKCI 2091/4885TLR8 1022/4885ESR1 2777/4885 |
| US-20100178647-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | MPL, THPO, PFKP | PRKCI 1398/4885TLR8 4172/4885ESR1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.